Corporate profile
- Corporate name
- Epsilon Molecular Engineering, Inc.
- Location
- Office&lab: Rm208, Research bldg. of Open Innovation Center in Saitama University, 255 Shimo-okubo, Sakura-ku, Saitama city, Saitama 338-8570 Japan
- Representative director
- Representative director (CEO): Naoto Nemoto, Ph. D
- Establishment
- August 19, 2016
- Capital stock
- JPY 10,000,000
- Business description
- Research and development of biotechnology
- Number of employees
- 21 (January. 2023)
Mission and Vision
Mission
- Biomolecules which enable to be substitution of pervious antibody medications. The biomolecules which achieve the development of new medications which can cure severe diseases/conditions (their medications are categorized as “Unmet Medical Needs” and could not cure with previous antibody medications).
- The biomolecules which show beneficial effect based on concept of new treatments.
- The biomolecules which can address the social and economical issues (e.g. low-cost medications).
We believe these next generation biomolecules are VHH (variable domain of heavy chain of heavy chain antibody) and peptide aptamer. Therefore, we have been working for implementation of VHH and peptide aptamer in medical field and our life. We believe this movement support affluent society.
Vision
In our society today, innovation of new technologies such as AI have been dramatically developed and values in the society have been changing. These changes affect research and development field and the expectations for research and development field also have been dramatically changing. In the medical field, more and more individualization of therapy become important. For the new generation of medical field, we need to improve the previous medications which have drawbacks, and develop innovative diagnostics and therapeutics with new concepts. In EME, we provide innovative and high-functioning biomolecules to the world with our high through put evolutionary molecular engineering technology. We believe this is our way to approach the social contributions for the world.
Management
Naoto NemotoRepresentative director, CEO
- 1996
- Postdoctoral fellow, Mitsubishi Chemical Institute of Life Science Inc.
- 1999
- General Manager, Research Planning Department, Biovision Capital Corp.
- 2003
- Invited Researcher, National Institute of Advanced Industrial Science and Technology (AIST)
- 2006
- Executive Officer and CSO, Janusys Corp.
- 2008
- Associate Professor, Department of Functional Materials Science, Graduate School of Science and Engineering, Saitama University
- 2015
- Professor, Department of Functional Materials Science, Graduate School of Science and Engineering, Saitama University
- 2016
- Director, Epsilon Molecular Engineering Inc.
- 2017
- Representative director, CEO, Epsilon Molecular Engineering Inc.
Masayuki TsuchiyaDirector, CTO
- 1983
- Graduate school of Engineering, Saitama University. Chugai Pharmaceutical Co., Ltd. New Drug Research Institute.
- 1984 1986
- Institute of Medical Science, The University of Tokyo (Cloning of G-CSF gene).
- 1990 1992
- Visiting Researcher fellow, MRC (Humanization of Anti-IL-6 Receptor antibodies)
- 2002
- General Manager, Genome Antibody Research Department, Chugai Pharmaceutical co., LTD
- 2005
- General Manager, Drug Discovery Planning and Promotion Department, Chugai Pharmaceutical co., LTD
- 2007 2014
- General Manager, Strategic Planning and Promotion Department, Chugai Pharmaceutical co., LTD
- 2015
- Senior Manager Academic Communications, The Tokyo Biochemical Research Foundation Comprehensive Academy for Advanced Oncology Unit (CHAAO)
- 2018
- Director, Epsilon Molecular Engineering Inc.
Scientific Advisory Boards
Yuzuru Husimi
Emeritus professor of Saitama Univ./ Evolutionary molecular engineering
Junichi Nakai
Tohoku Univ./Bioimaging
Tai Kubo
National Institute of Advanced Industrial Science and Technology (AIST)/Membrane proteins
Yuzuru Tozawa
Saitama Univ./Cell-free translation system
Takuya Terai
Graduate School science system graduate course of Tokyo Univ./Chemical biology
Kenzo Fujimoto
Japan Advanced Institute of Science and Technology (JAIST)/Nucleic acids chemistry
Yasuhiro Matsunaga
Graduate School of Science and Engineering, Saitama University
History
- 1985The research of evolutionary molecular engineering has started at Saitama University (Japan).
- 1997In vitro virus (mRNA display) method (one of virus-like genotype-phenotype linking strategies) was developed by Dr. Nemoto, Prof. Husimi, Dr. Yanagawa (Mitsubishi Chemical Institute of Life Sciences & Saitama University).
- 2008cDNA display method (improved version of mRNA display) was developed by Dr. Nemoto and his colleagues at Saitama-Bio project (JST)/ The National Institute of Advanced Industrial Science and Technology (AIST)/ Saitama University.
- 2014High-speed preparation method of cDNA display was developed by collaborating with Prof. Fujimoto (Japan Advanced Institute of Science and Technology; JAIST).
- 2015Filing of patent application for high-throughput system of cDNA display screening (exclusive license for use of the patent from Saitama University)
- 2016/8Established in Saitama University.
- 2017/4Started business at Open Innovation Research Center of Saitama University.
- 2017/9Adopted as NEDO-STS Grant : New Energy and Industrial Technology Development Organization (NEDO) commercialization support for the Seed-stage Technology-based Startups (STS).
- 2018/9Adopted as Research and Development Grant of Mitsubishi UFJ Technology Development Foundation (MU-TECH)
- 2019/3Awarded the winner of Real Tech Venture of the Year 2019 (Startup Category)
- 2020/1Office established in front of the main entrance of Saitama University, Sakura-ku, Saitama-city, Saitama, Japan
- 2020/7Selected a subsidy from Ministry of Economy The Small and Medium Enterprise Agency Strategic Foundational Technology Improvement Support Operation
- 2020/10Selected a subsidy from Japan Agency for Medical Research and Development(AMED), ″Development of medicine against COVID-19”